Por favor, use este identificador para citar o enlazar este ítem: http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/3268
Multidrug treatment with nelfinavir and cepharanthine against COVID-19
Hirofumi Ohashi.
Koichi Watashi.
Wakana Saso.
Kaho Shionoya.
Shoya Iwanami.
Takatsugu Hirokawa.
Tsuyoshi Shirai.
Shigehiko Kanaya.
Yusuke Ito.
Kwang Su Kim.
Kazane Nishioka.
Shuji Ando.
Keisuke Ejima.
Yoshiki Koizumi.
Tomohiro Tanaka.
Shin Aoki.
Kouji Kuramochi.
Tadaki Suzuki.
Katsumi Maenaka.
Tetsuro Matano.
Masamichi Muramatsu.
Masayuki Saijo.
Kazuyuki Aihara.
Shingo Iwami.
Makoto Takeda.
Jane McKeating.
Takaji Wakita.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1101/2020.04.14.039925
Antiviral treatments targeting the emerging coronavirus disease 2019 (COVID-19) are urgently required. We screened a panel of already-approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identified two new antiviral agents: the HIV protease inhibitor Nelfinavir and the anti-inflammatory drug Cepharanthine. In silico modeling shows Nelfinavir binds the SARS-CoV-2 main protease consistent with its inhibition of viral replication, whilst Cepharanthine inhibits viral attachment and entry into cells. Consistent with their different modes of action, in vitro assays highlight a synergistic effect of this combined treatment to limit SARS-CoV-2 proliferation. Mathematical modeling in vitro antiviral activity coupled with the known pharmacokinetics for these drugs predicts that Nelfinavir will facilitate viral clearance. Combining Nelfinavir/Cepharanthine enhanced their predicted efficacy to control viral proliferation, to ameliorate both the progression of disease and risk of transmission. In summary, this study identifies a new multidrug combination treatment for COVID-19.
www.biorxiv.org
2020
Artículo
https://www.biorxiv.org/content/10.1101/2020.04.14.039925v1.full.pdf
Inglés
VIRUS RESPIRATORIOS
Aparece en las colecciones: Artículos científicos

Cargar archivos:


Fichero Tamaño Formato  
1103993.pdf4.18 MBAdobe PDFVisualizar/Abrir